Effect of Oxaliplatin on Voltage-Gated Sodium Channels in Peripheral Neuropathic Pain

被引:7
|
作者
Kim, Woojin [1 ]
机构
[1] Kyung Hee Univ, Dept Physiol, Coll Korean Med, Seoul 02453, South Korea
关键词
allodynia; oxaliplatin; peripheral neuropathic pain; voltage-gated sodium channel; INDUCED NEUROTOXICITY; ANTICANCER AGENT; PREVENTION; NA+; EXPRESSION; DULOXETINE; POTENTIALS; MECHANISMS; MANAGEMENT; JUNCTIONS;
D O I
10.3390/pr8060680
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
Oxaliplatin is a chemotherapeutic drug widely used to treat various types of tumors. However, it can induce a serious peripheral neuropathy characterized by cold and mechanical allodynia that can even disrupt the treatment schedule. Since the approval of the agent, many laboratories, including ours, have focused their research on finding a drug or method to decrease this side effect. However, to date no drug that can effectively reduce the pain without causing any adverse events has been developed, and the mechanism of the action of oxaliplatin is not clearly understood. On the dorsal root ganglia (DRG) sensory neurons, oxaliplatin is reported to modify their functions, such as the propagation of the action potential and induction of neuropathic pain. Voltage-gated sodium channels in the DRG neurons are important, as they play a major role in the excitability of the cell by initiating the action potential. Thus, in this small review, eight studies that investigated the effect of oxaliplatin on sodium channels of peripheral neurons have been included. Its effects on the duration of the action potential, peak of the sodium current, voltage-response relationship, inactivation current, and sensitivity to tetrodotoxin (TTX) are discussed.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Dysregulation of voltage-gated sodium channels by ubiquitin ligase NEDD4-2 in neuropathic pain
    Laedermann, Cedric J.
    Cachemaille, Matthieu
    Kirschmann, Guylene
    Pertin, Marie
    Gosselin, Romain-Daniel
    Chang, Isabelle
    Albesa, Maxime
    Towne, Chris
    Schneider, Bernard L.
    Kellenberger, Stephan
    Abriel, Hugues
    Decosterd, Isabelle
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (07): : 3002 - 3013
  • [32] Voltage-gated sodium channels and hyperalgesia
    Lai, J
    Porreca, F
    Hunter, JC
    Gold, MS
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2004, 44 : 371 - 397
  • [33] Voltage-gated sodium channels in epilepsy
    Köhling, R
    EPILEPSIA, 2002, 43 (11) : 1278 - 1295
  • [34] Fenestropathy of Voltage-Gated Sodium Channels
    Gamal El-Din, Tamer M.
    Lenaeus, Michael J.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Voltage-gated sodium channels in cancers
    Liu, Hengrui
    Weng, Jieling
    Huang, Christopher L. -H.
    Jackson, Antony P.
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [36] Nomenclature of voltage-gated sodium channels
    Goldin, AL
    Barchi, RL
    Caldwell, JH
    Hofmann, F
    Howe, JR
    Hunter, JC
    Kallen, RG
    Mandel, G
    Meisler, MH
    Netter, YB
    Noda, M
    Tamkun, MM
    Waxman, SG
    Wood, JN
    Catterall, WA
    NEURON, 2000, 28 (02) : 365 - 368
  • [37] VOLTAGE-GATED SODIUM AND POTASSIUM CHANNELS
    RAMASWAMI, M
    CURRENT SCIENCE, 1992, 62 (04): : 341 - 354
  • [38] Voltage-gated calcium channels and pain
    Cao, Yu-Qing
    PAIN, 2006, 126 (1-3) : 5 - 9
  • [39] Voltage-gated sodium channel blockers: New perspectives in the treatment of neuropathic pain
    Alcantara Montero, A.
    Sanchez Carnerero, C. I.
    NEUROLOGIA, 2021, 36 (02): : 169 - 171
  • [40] Licochalcone Mediates the Pain Relief by Targeting the Voltage-Gated Sodium ChannelS
    Zhao, Qianru
    Zhang, Xu
    Long, Siru
    Wang, Shaobing
    Yu, Hui
    Zhou, Yongsheng
    Li, Yi
    Xue, Lu
    Hu, Yan
    Yin, Shijin
    MOLECULAR PHARMACOLOGY, 2023, 104 (04) : 133 - 143